Anaptysbio (ANAB) Net Cash Flow Growth (3y) (2019 - 2026)
Anaptysbio (ANAB) Net Cash Flow Growth (3y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,132.22 Bn | 67,131.94 Bn | - | -50.33% |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 973.81 Bn | 973.81 Bn | - | - |
| 4 | BeOne Medicines | 471.45 Bn | 466.66 Bn | 1.35 Bn | 38.47% |
| 5 | Vertex Pharmaceuticals | 122.00 Bn | 114.75 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 69.99 Bn | 61.23 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.86 Bn | 50.67 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.46 Bn | 959.66 Mn | 32.17% |
| 10 | Anaptysbio | 1.56 Bn | 1.27 Bn | - | -23.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -23.84% |
| Dec 31, 2025 | 115.87% |
| Sep 30, 2025 | 91.13% |
| Jun 30, 2025 | 16.91% |
| Mar 31, 2025 | 57.97% |
| Dec 31, 2024 | -34.44% |
| Sep 30, 2024 | 208.62% |
| Jun 30, 2024 | -27.77% |
| Mar 31, 2024 | -19.27% |
| Dec 31, 2023 | -38.37% |
| Sep 30, 2023 | 9.49% |
| Jun 30, 2023 | -45.22% |
| Mar 31, 2023 | 82.51% |
| Dec 31, 2022 | 45.40% |
| Sep 30, 2022 | -33.17% |
| Jun 30, 2022 | -62.95% |
| Mar 31, 2022 | -249.06% |
| Dec 31, 2021 | 42.38% |
| Sep 30, 2021 | -74.17% |
| Jun 30, 2021 | 80.43% |